- Home
- MSTR vs EW Comparison
MSTR vs EW Comparison
Compare MSTR & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSTR | EW |
|---|---|---|
| Founded | 1989 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4B | 49.5B |
| IPO Year | 1998 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MSTR | EW |
|---|---|---|
| Price | $146.59 | $82.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $466.00 | $96.79 |
| AVG Volume (30 Days) | ★ 21.7M | 3.7M |
| Earning Date | 02-05-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 27.34 | 2.33 |
| Revenue | $474,942,000.00 | ★ $5,883,800,000.00 |
| Revenue This Year | $4.77 | $14.29 |
| Revenue Next Year | $2.91 | $9.73 |
| P/E Ratio | ★ $5.48 | $34.92 |
| Revenue Growth | 1.65 | ★ 10.60 |
| 52 Week Low | $139.36 | $65.94 |
| 52 Week High | $457.22 | $87.89 |
Technical Indicators
Market Signals| Indicator | MSTR | EW |
|---|---|---|
| Relative Strength Index (RSI) | 38.17 | 43.71 |
| Support Level | $139.36 | $80.44 |
| Resistance Level | $165.72 | $82.82 |
| Average True Range (ATR) | 9.39 | 1.77 |
| MACD | -1.15 | -0.28 |
| Stochastic Oscillator | 15.50 | 34.75 |
Price Performance
Historical ComparisonAbout MSTR MicroStrategy Incorporated
Strategy Inc is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provides industry AI-powered enterprise analytics software.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.